Gastrospirillum Hominis—Associated Chronic Active Gastritis

Abstract Objectives.—To describe the endoscopic biopsy pathology of Helicobacter pylori gastritis, compare bacterial detection by immunohistochemistry using a specific antibody with the Genta stain, and to compare the relative costs of the 2 techniques. Design.—One hundred cases of gastritis identified as positive for H pylori by Genta stain and 100 cases considered negative by the same technique were stained using an anti-H pylori–specific polyclonal antibody. Laboratory reagent and labor costs for the 2 methods were compared. Results.—Chronic active gastritis with lymphoid follicles was significantly associated with H pylori infection (P < .0001). The immunohistochemical method had a sensitivity of 97% and a specificity of 98% compared with the Genta stain, with strong agreement for grading density of organisms (κ = 0.85; P < .001). Reagent costs were similar for both methods, but immunohistochemistry using an autoimmunostainer required less dedicated technical time and hence was less expensive than the Genta stain. Conclusions.—Immunohistochemistry using a specific antibody is an accurate and cost-effective method for H pylori detection in gastric biopsies.

Download Full-text

GASTROSPIRILLUM HOMINIS

The Lancet ◽

10.1016/s0140-6736(89)90434-0 ◽

1989 ◽

Vol 334 (8657) ◽

pp. 252-253

Keyword(s):

Gastrospirillum Hominis

Download Full-text

DO H. PYLORI STATUS AND SMALL INTESTINAL BACTERIAL OVERGROWTH DETERMINE THE CLINICAL COURSE OF CHRONIC ACTIVE GASTRITIS IN PATIENTS WITH TYPE 2 DIABETES MELLITUS?

Wiadomości Lekarskie ◽

10.36740/wlek202006127 ◽

2020 ◽

Vol 73 (6) ◽

pp. 1223-1228

Author(s):

Tetiana O. Radionova ◽

Igor M. Skrypnyk ◽

Ganna S. Maslova

Keyword(s):

Diabetes Mellitus ◽

Type 2 Diabetes ◽

Epigastric Pain ◽

Bacterial Overgrowth ◽

Small Intestinal Bacterial Overgrowth ◽

Postprandial Fullness ◽

Chronic Active Gastritis ◽

Intestinal Bacterial Overgrowth ◽

Small Intestinal

The aim: To define clinical peculiarities of chronic active gastritis in patients with type 2 diabetes mellitus (T2DM) considering Helicobacter pylori (HP) status and small intestinal bacterial overgrowth (SIBO). Materials and methods: 172 patients with chronic active gastritis were enrolled in the study, 92 out of them had concomitant T2DM. Symptoms were collected with the questionnaire, HP infection was diagnosed with stool antigen test, SIBO was assessed with glucose hydrogen breath test. Results: 87.5% (n=70) patients with chronic gastritis without DM had epigastric pain, however those with T2DM reported pain only in 41.3% (n=38) cases. Other symptoms included: nausea, bloating, early satiety, postprandial fullness, heartburn, belching and vomiting. HP infection in patients with chronic gastritis and concomitant T2DM is significantly associated with symptoms of epigastric pain (OR=2.78, 95%CI 0.92-8.41), bloating (OR=3.92, 95%CI 1.40-10.99), nausea (OR=2.32, 95%CI 0.85-0.6.30), postprandial fullness (OR=1.45, 95%CI 0.54-3.87) and belching (OR=1.01, 95%CI 0.32-3.16), whereas SIBO – with bloating (OR=8.82, 95%CI 2.88-27.01), nausea (OR=5.15, 95%CI 1.88-14.10) and belching (OR=2.53, 95%CI 0.67-9.52). Conclusions: Patients with T2DM and chronic active gastritis report epigastric pain significantly less than non-diabetics. HP infection probably plays a prominent role in development of epigastric pain in patients with T2DM. Additionally, HP is linked to SIBO, which may lead to bloating, belching and nausea onset.

Download Full-text

Characterization of MultipleHelicobacter bizzozeroniiIsolates From a Finnish Patient With Severe Dyspeptic Symptoms and Chronic Active Gastritis

Helicobacter ◽

10.1111/j.1523-5378.2009.00730.x ◽

2010 ◽

Vol 15 (1) ◽

pp. 58-66 ◽

Cited By ~ 29

Author(s):

Rauni KivistÃ¶ ◽

JÃ¼ri Linros ◽

Mirko Rossi ◽

Hilpi Rautelin ◽

Marja-Liisa HÃ¤nninen

Keyword(s):

Chronic Active Gastritis ◽

Finnish Patient ◽

Dyspeptic Symptoms

Download Full-text

The role of acid inhibition in Helicobacter pylori eradication

F1000Research ◽

10.12688/f1000research.8598.1 ◽

2016 ◽

Vol 5 ◽

pp. 1747 ◽

Cited By ~ 10

Author(s):

David R. Scott ◽

George Sachs ◽

Elizabeth A. Marcus

Keyword(s):

Helicobacter Pylori ◽

Urease Activity ◽

Eradication Therapy ◽

Acid Inhibition ◽

Acid Suppression ◽

Helicobacter Pylori Eradication ◽

Ulcer Disease ◽

Chronic Active Gastritis ◽

H Pylori

Infection of the stomach by the gastric pathogen Helicobacter pylori results in chronic active gastritis and leads to the development of gastric and duodenal ulcer disease and gastric adenocarcinoma. Eradication of H. pylori infection improves or resolves the associated pathology. Current treatments of H. pylori infection rely on acid suppression in combination with at least two antibiotics. The role of acid suppression in eradication therapy has been variously attributed to antibacterial activity of proton pump inhibitors directly or through inhibition of urease activity or increased stability and activity of antibiotics. Here we discuss the effect of acid suppression on enhanced replicative capacity of H. pylori to permit the bactericidal activity of growth-dependent antibiotics. The future of eradication therapy will rely on improvement of acid inhibition along with current antibiotics or the development of novel compounds targeting the organism’s ability to survive in acid.

Download Full-text